Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

28.55 +1.49 (+5.51%)
Streaming Delayed Price Updated: 11:26 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 Next >
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What 6 Analyst Ratings Have To Say About Arcturus Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Arcturus Therapeutics (NASDAQ:ARCT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Upgrades 
Via Benzinga
Expert Ratings for Arcturus Therapeutics
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings: 
Via Benzinga
Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
Arcturus Therapeutics's Earnings Outlook
Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months... 
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 250 points on Wednesday. 
Via Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 40.0% to $1.4 during Wednesday's pre-market session. The company's market cap stands at $39.8 million.... 
Via Benzinga
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical... 
Via Benzinga
Arcturus Therapeutics's Earnings Outlook
Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Calliditas Therapeutics (NASDAQ:CALT... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
31 Stocks Moving In Thursday's Mid-Day Session
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal... 
Via Benzinga
Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83
Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level. 
Via Investor's Business Daily
Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.